RxDoctor Payments Data

Sonikpreet Aulakh, MD

Hematology & Oncology · Morgantown, WVNPI 1649612722

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Novocure Inc. at 52.9% of the total. Reporting peaked in 2024 at $9,683 and has fallen 86.1% since, to $1,350 in 2025.

$17,144in general payments, 2019–2025

Across 30 payments — averaging $571.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novocure Inc.$9K
  • Springworks Therapeutics, Inc.$4K
  • Servier Pharmaceuticals LLC$2K
  • Caris MPI, Inc.$1K
  • AstraZeneca$217
  • GT Medical Technologies, Inc$197
  • plus $264 from 6 others
$96,451in research payments, 2019–2025

Across 53 payments — averaging $1819.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novocure GmbH$53K
  • Blue Earth Diagnostics$28K
  • Bayer$15K

What the payments were for

  • Consulting fees$9,90058%
  • Speaking & faculty fees$4,67527%
  • Travel & lodging$1,4679%
  • Food & beverage$1,0036%
  • Education$991%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,144 in reported general payments places this provider in the 85th percentile of 72 hematology & oncology providers in West Virginia.

See all hematology & oncology providers in West Virginia

Medicare billing

Part B allowed, 2024
$22,080
Medicare patients
98
Services billed
225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KoselugoSelumetinib Sulfate21$382,719
EliquisApixaban13$7,378
Levetiracetam42$1,218
Ondansetron Hcl43$815
Dexamethasone34$513
Hydrocortisone20$384
Donepezil Hcl26$186
Prochlorperazine Maleate12$154
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim42$84
Gabapentin21$82
Prednisone30$65
Tramadol Hcl16$40

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaKoselugo$217$382,71921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 72 hematology & oncology providers in West Virginia.

Other hematology & oncology in Morgantown

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →